Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Qiagen ( (QGEN) ) is now available.
The Netherlands Authority For the Financial Markets (AFM) has notified QIAGEN N.V. about a significant voting rights announcement involving Goldman Sachs Group Inc. The notification details various financial instruments and shares held by Goldman Sachs entities, indicating both real and potential voting rights and capital interests in QIAGEN. This disclosure could impact QIAGEN’s market perception and stakeholder relations, reflecting the extent of Goldman Sachs’ involvement in the company’s financial structure.
The most recent analyst rating on (QGEN) stock is a Hold with a $50.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V. is a company operating in the biotechnology industry, providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is listed on several stock exchanges including Frankfurt, NYSE, and SIX, and has a market focus on providing innovative solutions for the life sciences and healthcare sectors.
Average Trading Volume: 1,172,126
Technical Sentiment Signal: Strong Buy
Current Market Cap: $9.88B
Find detailed analytics on QGEN stock on TipRanks’ Stock Analysis page.